Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Hannah Fraser, Natasha Martin, Henrikki Brummer-Korvenkontio, Patrizia Carrieri, Olav Dalgard, John Dillon, David Goldberg, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kaberg, Amy Matser, Mojca Matičič, Håvard Midgard, Viktor Mravčík, Anne Øvrehus, Maria Prins, Jens Reimer, Geert Robaeys, Bernd Schulte, Daniela van SantenRuth Zimmermann, Peter Vickerman, Matthew Hickman

Research output: Contribution to journalArticle (Academic Journal)peer-review

70 Citations (Scopus)
205 Downloads (Pure)


Background: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical to eliminating HCV in Europe. We estimate impact of current and scaled-up HCV treatment with and without scaling-up opioid substitution therapy (OST) and needle and syringe programmes (NSP) across Europe over the next 10 years.

Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST and NSP coverage from 11 European settings. We parameterized a HCV transmission model to setting-specific data that projects chronic HCV prevalence and incidence among PWID.

Results: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. Current treatment rates using new direct acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia and Amsterdam. Doubling HCV-treatment rates will reduce prevalence in other sites (12-24%, Belgium/Denmark/Hamburg/Norway/Scotland) but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100pyrs or less in 10 years. Moderate to substantial increases in current treatment rates are required to achieve the same impact elsewhere, from 1.4-3 times (Czech Republic/France), 5-17 times (France/Scotland/Hamburg/Norway/Denmark/Belgium/Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%.

Conclusions: Scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.
Original languageEnglish
Pages (from-to)402-411
JournalJournal of Hepatology
Issue number3
Early online date25 Oct 2017
Publication statusPublished - 1 Mar 2018


Dive into the research topics of 'Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe'. Together they form a unique fingerprint.

Cite this